Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer : a multicenter retrospective study

Nakano, Shintaro; Yuki, Satoshi; Kawamoto, Yasuyuki; Nakatsumi, Hiroshi; Ando, Takayuki; Kajiura, Shinya; Yoshikawa, Ayumu; Harada, Kazuaki; Hatanaka, Kazuteru; Tanimoto, Aya; Ishiguro, Atsushi; Honda, Takuya; Dazai, Masayoshi; Sasaki, Takahide; Sakamoto, Naoya; Komatsu, Yoshito

Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer : a multicenter retrospective study

Nakano, Shintaro; Yuki, Satoshi; Kawamoto, Yasuyuki et al.

International journal of clinical oncology, 2021, 25, 1800-1806

Permalink : https://hdl.handle.net/2115/79364

このアイテムのアクセス数:657件（2026-08-16 09:53 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1007/s10147-020-01720-y			13

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/79364
タイトル	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer : a multicenter retrospective study
著者	Nakano, Shintaro ; Yuki, Satoshi ; Kawamoto, Yasuyuki ; Nakatsumi, Hiroshi ; Ando, Takayuki ; Kajiura, Shinya ; Yoshikawa, Ayumu ; Harada, Kazuaki ; Hatanaka, Kazuteru ; Tanimoto, Aya ; Ishiguro, Atsushi ; Honda, Takuya ; Dazai, Masayoshi ; Sasaki, Takahide ; Sakamoto, Naoya ; Komatsu, Yoshito
著者名 Nakano, Shintaro
著者名 Yuki, Satoshi
e-Rad_Researcher 60755601 著者名 Kawamoto, Yasuyuki
e-Rad_Researcher 50735157 著者名 Nakatsumi, Hiroshi
著者名 Ando, Takayuki
e-Rad_Researcher 70456383 著者名 Kajiura, Shinya
著者名 Yoshikawa, Ayumu
著者名 Harada, Kazuaki
著者名 Hatanaka, Kazuteru
著者名 Tanimoto, Aya
著者名 Ishiguro, Atsushi
著者名 Honda, Takuya
著者名 Dazai, Masayoshi
著者名 Sasaki, Takahide
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
e-Rad_Researcher 60333598 著者名 Komatsu, Yoshito
言語	英語
キーワード	Gastric cancer
キーワード	Irinotecan
発行日	2021-10
出版者	Springer
収録物名	International journal of clinical oncology
巻(号)	25
ページ	1800-1806
抄録	Background It is unclear whether the UGT1A1 status, single heterozygous (SH) or wild type (WT), is associated with the efficacy and toxicity of irinotecan monotherapy in advanced gastric cancer (AGC). We investigated the association between clinical outcomes (efficacy and safety) and UGT1A1 status in patients who received irinotecan monotherapy. Methods We evaluated AGC patients who received irinotecan monotherapy between January 2011 and December 2017. Efficacy was assessed according to overall survival (OS) and progression-free survival (PFS). Toxicity was graded using the Common Toxicity Criteria for Adverse Events (version 4.0). Results A total of 100 patients were evaluated (62 and 38 patients with UGT1A1 WT and SH, respectively). In the WT and SH groups, the irinotecan dose was reduced in 19 (30.6%) and 18 (47.2%) patients (p = 0.135), respectively; treatment was delayed due to adverse events (AEs) in 19 (30.6%) and 13 (34.2%) patients (p = 0.826), respectively; the median PFS was 3.15 and 3.25 months (HR, 0.734; 95% CI 0.465-1.158;p = 0.184), respectively; and the median OS was 10.4 and 7.26 months (HR, 1.137; 95% CI 0.752-1.721;p = 0.543), respectively. Severe hematological AEs (Grade >= 3) were significantly more frequent in the SH group than in the WT group (63% vs. 36%;p = 0.008), while severe non-hematological AEs was not significantly different (16.0% vs. 6.5%;p = 0.173). Conclusion There was no significant difference in the efficacy of irinotecan monotherapy between UGT1A1 WT and UGT1A1 SH, but UGT1A1 SH was associated with a high frequency of severe hematological toxicity.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
PISSN	1341-9625
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1007/s10147-020-01720-y